Phase Bioscience, a development stage biotechnology company has licensed its patented deltaPhase process to Centocor Research and Development for use in its research applications.
Subscribe to our email newsletter
Under the terms of the agreement, Centocor will have rights to utilize the deltaPhase technology in their research. PhaseBio’s deltaPhase technology is said to offer new solutions for the production and purification of protein-based therapeutics, including polypeptides, proteins or antibodies and provides substantial advantages over current biological production methods.
Clay Thorp, chairman of the board, Phase Bioscience, said: “We are extremely pleased that Centocor has decided to extend their successful collaboration with PhaseBio.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.